Previous 10 | Next 10 |
home / stock / esalf / esalf news
Eisai to Present Latest Data on Perampanel at The 77th American Epilepsy Society (AES) Annual Meeting TOKYO, Nov 22, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company will have a total of nine poster presentations, including the latest data on its in-house dis...
LEQEMBI Wins Best New Drug And Clinical Advance of The Year at The Scrip Awards 2023 TOKYO and CAMBRIDGE, Mass., Nov 20, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that Alzheimer's disease (AD) treatment LEQEMBI (lecanemab-irmb) was awarde...
2023-11-08 07:40:46 ET More on Biogen Biogen - Revised Revenue Forecasting To 2030 - New CEO Faces Major Challenges Biogen Inc. (BIIB) Management presents at Decentralized Clinical Trials in Focus Conference (Transcript) Biogen Inc. (BIIB) Morgan Stanley 21st Annual ...
2023-11-07 16:25:19 ET Eisai Co Ltd (ESALF) Q2 2023 Earnings Conference Call November 07, 2023, 01:00 ET Company Participants Haruo Naito - CEO Lynn Kramer - VP & Chief Clinical Officer, Alzheimer's Disease and Brain Health Yasunobu Kai - Former Senior Group ...
2023-11-07 06:59:00 ET More on Biogen, Eisai, etc. Stocks To Watch: Tesla, Netflix, And AT&T Headline Big Week Of Earnings Biogen - Revised Revenue Forecasting To 2030 - New CEO Faces Major Challenges Biogen Inc. (BIIB) Management presents at Decentralized Clinic...
2023-10-26 13:48:39 ET More on BioVie, Cognition, etc. BioVie: Bullish Signals From Blinded Data Presentation (Rating Upgrade) Prothena: Switching From 'Hold' To 'Buy' On Lead Alzheimer's Drug Promise BioVie: Well-Powered Phase 3 Trial In Alzheimer's Could Greatly Be...
2023-10-25 17:51:31 ET More on Biogen Biogen - Revised Revenue Forecasting To 2030 - New CEO Faces Major Challenges Biogen Inc. (BIIB) Management presents at Decentralized Clinical Trials in Focus Conference (Transcript) Biogen Inc. (BIIB) Morgan Stanley 21st Annual ...
2023-10-25 13:59:34 ET More on Cassava Sciences Cassava Sciences' Integrity Under Scrutiny Following CUNY Misconduct Claims Cassava Sciences: Update Following Leaked CUNY Report, Fundamentals Remain Unchanged Cassava Sciences: Unconvincing Open Label Studies, Upcomin...
LEQEMBI (lecanemab-Irmb) Named One of Time's Best Inventions of 2023 TOKYO, Oct 25, 2023 - (JCN Newswire) - Eisai Co. Ltd. announced today that TIME has selected Alzheimer's disease (AD) treatment LEQEMBI (lecanemab-irmb) as one of THE BEST INVENTIONS of 2023 in the Medical Care cat...
Eisai to Present New Data from LEQEMBI (Lecanemab-Irmb) Phase 3 Clarity Ad Study and Other Alzheimer's Disease Pipeline Research at The Clinical Trials on Alzheimer's Disease (CTAD) Conference TOKYO, Oct 16, 2023 - (JCN Newswire) - Eisai Co. Ltd announced today that the company will...
News, Short Squeeze, Breakout and More Instantly...
Eisai Co Ltd Company Name:
ESALF Stock Symbol:
OTCMKTS Market:
"LEQEMBI" Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel TOKYO and CAMBRIDGE, Mass., July 12, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMB...
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Hong Kong TOKYO and CAMBRIDGE, Mass., July 11, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the Department of Health in HongKong has approved humanized anti-soluble aggregated ...
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC) TOKYO, July 2, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has agreed to end its global strategic collaboration with Bristol Myers Squi...